Kogavant (Ticagrelor)

Kogavant (ticagrelor) is used as an antiplatelet therapy in the management of acute coronary syndromes and related cardiovascular conditions.

• Acute coronary syndrome: reduces the risk of cardiovascular death, myocardial infarction and stroke.
• Secondary prevention after myocardial infarction: lowers the incidence of recurrent ischemic events.
• Patients undergoing percutaneous coronary intervention (PCI): diminishes thrombotic complications associated with the procedure.

• Ticagrelor is a reversible, direct‑acting oral antagonist of the platelet P2Y12 ADP receptor. By binding to this receptor, it blocks ADP‑mediated activation of the GPIIb/IIIa complex, thereby inhibiting platelet aggregation and thrombus formation without requiring metabolic activation.

Ticagrelor may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Dyspnea: shortness of breath, often mild to moderate.
• Bleeding: including bruising, nosebleeds, and gastrointestinal hemorrhage.
• Headache: transient and usually mild.
• Nausea: occasional gastrointestinal upset.
• Dizziness: sensation of light‑headedness.
• Hypotension: mild drops in blood pressure.

Serious or Rare Side Effects

• Severe bleeding: intracranial or life‑threatening hemorrhage.
• Thrombocytopenia: marked reduction in platelet count.
• Hepatic injury: elevated liver enzymes or hepatitis.
• Allergic reactions: rash, angioedema, or anaphylaxis.
• Cardiac arrhythmias: rare cases of ventricular tachycardia.

When prescribing Kogavant, clinicians should observe several safety considerations.

• Bleeding risk assessment: evaluate for active or recent bleeding before initiation.
• Dyspnea monitoring: watch for new or worsening shortness of breath.
• Contraindication in pregnancy: avoid use as it is contraindicated.
• Hepatic impairment: use with caution in patients with moderate liver disease.
• Drug‑specific warnings: do not combine with other potent antiplatelet agents without justification.
• Store at below 25°C: keep in the original pack, protect from moisture.

Ticagrelor interacts with several medicines that can alter its antiplatelet effect or increase bleeding risk.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ticagrelor exposure.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.
• Concurrent use of other antiplatelet agents (e.g., high‑dose aspirin): heightens bleeding risk.

Moderate Interactions (Monitor Closely)

• NSAIDs (e.g., ibuprofen): may increase gastrointestinal bleeding.
• SSRIs or SNRIs (e.g., fluoxetine, venlafaxine): potential additive bleeding effect.
• Anticoagulants (e.g., warfarin, DOACs): require careful monitoring of coagulation parameters.